Per-Ola Freskgård, Christer Möller, Lars Lannfelt on Of Four Aβ Antibodies, Only Aducanumab Stems Tide of Toxic Oligomers
COMMENT The authors claim, based on this modeling, that aducanumab selectively reduces the secondary nucleation rate, solanezumab selectively inhibits primary nucleation, and bapineuzumab and gantenerumab act by reducing elongation of fibrils. Furthermore, the ...